<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d1 20130915//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">SAGE Open Med</journal-id><journal-id journal-id-type="iso-abbrev">SAGE Open Med</journal-id><journal-id journal-id-type="publisher-id">SMO</journal-id><journal-id journal-id-type="hwp">spsmo</journal-id><journal-title-group><journal-title>SAGE Open Medicine</journal-title></journal-title-group><issn pub-type="epub">2050-3121</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7686599</article-id><article-id pub-id-type="doi">10.1177/2050312120973499</article-id><article-id pub-id-type="publisher-id">10.1177_2050312120973499</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Kinetics and computational analysis of cholinesterase inhibition by
REVERC3, a bisdemethoxycurcumin-rich <italic>Curcuma longa</italic> extract:
Relevance to the treatment of Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1287-9617</contrib-id><name><surname>HV</surname><given-names>Sudeep</given-names></name><xref ref-type="corresp" rid="corresp1-2050312120973499"/></contrib><contrib contrib-type="author"><name><surname>Raj</surname><given-names>Amritha</given-names></name></contrib><contrib contrib-type="author"><name><surname>K</surname><given-names>Gouthamchandra</given-names></name></contrib><contrib contrib-type="author"><name><surname>S</surname><given-names>Chandrappa</given-names></name></contrib><contrib contrib-type="author"><name><surname>K</surname><given-names>Shyamprasad</given-names></name></contrib><aff id="aff1-2050312120973499">R&#x00026;D Center for Excellence, Vidya Herbs Pvt.
Ltd., Bangalore, India</aff></contrib-group><author-notes><corresp id="corresp1-2050312120973499">Sudeep HV, R&#x00026;D Center for Excellence,
Vidya Herbs Pvt. Ltd., No. 14/A, KIADB, Jigani Industrial Area, Anekal Taluk,
Bangalore 560 105, Karnataka, India. Email:
<email>research@vidyaherbs.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>11</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>8</volume><elocation-id>2050312120973499</elocation-id><history><date date-type="received"><day>22</day><month>7</month><year>2020</year></date><date date-type="accepted"><day>26</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p><bold>Objectives:</bold> Cholinesterase inhibition is a common strategy to treat
Alzheimer&#x02019;s disease. In this study, we have investigated the cholinesterase
inhibitory effects of a first-of-its-kind turmeric extract (REVERC3) having
enriched content of bisdemethoxycurcumin as major active curcuminoid.
<bold>Methods</bold>: The inhibition studies were performed using Ellman&#x02019;s
colorimetric assay. The kinetics of acetylcholinesterase and
butyrylcholinesterase was determined in the presence of REVERC3 using the
Lineweaver&#x02013;Burk double reciprocal plots. Furthermore, we used AutoDock tools to
predict the binding of bisdemethoxycurcumin with the active sites of
cholinesterases. <bold>Results</bold>: REVERC3 showed 4.8- and 5.39-fold higher
inhibitory potential of acetylcholinesterase and butyrylcholinesterase with IC50
values of 29.08 and 33.59&#x02009;&#x000b5;g/mL, respectively, compared to the regular turmeric
extract. The mode of binding of REVERC3 was competitive in the case of
acetylcholinesterase while it was uncompetitive for the inhibition of
butyrylcholinesterase. Docking analysis revealed that bisdemethoxycurcumin, the
major constituent of REVERC3, has different preferences of binding in the active
sites of acetylcholinesterase and butyrylcholinesterase. However, the best
binding pose predictions are in line with the experimental binding mode of the
cholinesterases. <bold>Conclusion</bold>: These results indicate that
bisdemethoxycurcumin-enriched turmeric extract could improve the cholinergic
functions via dual inhibition of cholinesterases. However, the predominant role
of bisdemethoxycurcumin in REVERC3 must be further validated using preclinical
studies and clinical trials.</p></abstract><kwd-group><kwd>Cognition deficits</kwd><kwd>cholinesterases</kwd><kwd>bisdemethoxycurcumin</kwd><kwd>turmeric</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2020</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-2050312120973499"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD) is the most common form of dementia affecting the geriatric
population worldwide.<sup><xref rid="bibr1-2050312120973499" ref-type="bibr">1</xref></sup> AD is characterized by the progressive loss of cognitive function leading to
irreversible neurodegenerative disorder.<sup><xref rid="bibr2-2050312120973499" ref-type="bibr">2</xref></sup> AD pathology includes the apoptotic death of cholinergic neurons in the
neocortical and limbic regions subsequently resulting in the decline of neurotransmission.<sup><xref rid="bibr3-2050312120973499" ref-type="bibr">3</xref></sup> Presumably, the cholinergic deficits result from tau hyperphosphorylation and
amyloid plaque formation.<sup><xref rid="bibr4-2050312120973499" ref-type="bibr">4</xref><xref rid="bibr5-2050312120973499" ref-type="bibr"/>&#x02013;<xref rid="bibr6-2050312120973499" ref-type="bibr">6</xref></sup> Patients
suffering from AD often experience the symptoms that typically include repetitive
questioning, confusion, and mood swings.<sup><xref rid="bibr7-2050312120973499" ref-type="bibr">7</xref></sup> The symptoms worsen over time with the patient experiencing delusion and aphasia.<sup><xref rid="bibr7-2050312120973499" ref-type="bibr">7</xref></sup></p><p>Reduced production of acetylcholine (ACh) leads to cognitive impairments such as
learning, memory, and attention.<sup><xref rid="bibr8-2050312120973499" ref-type="bibr">8</xref></sup> Acetylcholinesterase (AChE), the key enzyme involved in ACh metabolism is a
prime target in the treatment of AD.<sup><xref rid="bibr9-2050312120973499" ref-type="bibr">9</xref></sup> In addition, butyrylcholinesterase (BuChE) has also been reported to play a
role in the ACh metabolism at the later stages in AD pathology.<sup><xref rid="bibr10-2050312120973499" ref-type="bibr">10</xref></sup> Hence, it is of great interest to use the interventions that can act as dual
inhibitors of AChE as well as BuChE in the therapeutic strategy against AD. Several
drugs such as donepezil, galantamine, rivastigmine, and tacrine function as
inhibitors of AChE, thereby increasing the ACh levels.<sup><xref rid="bibr11-2050312120973499" ref-type="bibr">11</xref></sup> Rivastigmine and galantamine are known drugs for the inhibition of both AChE
and BuChE.<sup><xref rid="bibr12-2050312120973499" ref-type="bibr">12</xref>,<xref rid="bibr13-2050312120973499" ref-type="bibr">13</xref></sup> Despite being
efficacious, these drugs are associated with unwanted side effects which include
gastrointestinal irritations.<sup><xref rid="bibr14-2050312120973499" ref-type="bibr">14</xref>,<xref rid="bibr15-2050312120973499" ref-type="bibr">15</xref></sup></p><p>Complementary medicinal research in the development of effective treatment strategy
to combat AD and other neurodegenerative conditions is greatly appreciated. Such
treatments should ideally improve the quality of life and reduce the burden of
financial concerns experienced by the patients. Natural AChE inhibitors possess
other pharmacological attributes such as anti-inflammation and anti-oxidant
activities that make them useful as multi-target approaches against AD
progression.<sup><xref rid="bibr16-2050312120973499" ref-type="bibr">16</xref>,<xref rid="bibr17-2050312120973499" ref-type="bibr">17</xref></sup></p><p>Turmeric is a culinary spice used long since in Indian food and folkloric medicine.<sup><xref rid="bibr18-2050312120973499" ref-type="bibr">18</xref></sup> The medicinal properties of turmeric such as anti-inflammatory, anti-tumor,
and anti-oxidant effects are mostly attributed to the presence of the yellow pigment
curcumin.<sup><xref rid="bibr19-2050312120973499" ref-type="bibr">19</xref><xref rid="bibr20-2050312120973499" ref-type="bibr"/>&#x02013;<xref rid="bibr21-2050312120973499" ref-type="bibr">21</xref></sup> Other
curcuminoids such as bisdemethoxycurcumin (BDMC) and demethoxycurcumin (DMC) exhibit
synergistic effects with curcumin.<sup><xref rid="bibr22-2050312120973499" ref-type="bibr">22</xref></sup> The physiological benefits of BDMC include anti-inflammatory<sup><xref rid="bibr22-2050312120973499" ref-type="bibr">22</xref></sup> and anti-carcinogenic activities.<sup><xref rid="bibr23-2050312120973499" ref-type="bibr">23</xref>,<xref rid="bibr24-2050312120973499" ref-type="bibr">24</xref></sup> Previously, Kalayc&#x00131;o&#x0011f;lu et al.<sup><xref rid="bibr25-2050312120973499" ref-type="bibr">25</xref></sup> have reported the preliminary findings on the inhibitory potential of BDMC
against AChE. Here we have studied the kinetics of AChE and BuChE enzyme inhibition
by a BDMC-rich proprietary turmeric extract (REVERC3). Furthermore, in silico
docking studies were performed to predict the binding interaction of BDMC with the
catalytic sites of cholinesterases. Data from this study provide valuable
information on the potentials of BDMC as dual inhibitor of cholinesterases and its
possible role in slowing down cognitive decline.</p></sec><sec sec-type="materials|methods" id="section2-2050312120973499"><title>Materials and methods</title><sec id="section3-2050312120973499"><title>Materials</title><p>AChE (EC 3.1.1.7) from <italic>Electrophorus electricus</italic>, BuChE (EC
3.1.1.8) from equine serum, acetylthiocholine iodide (ATC), butyrylthiocholine
iodide (BTC), 5:5-dithiobis-2-nitrobenzoic acid (DTNB) were procured from Sigma
Aldrich (St. Louis, MO, USA). All chemicals used were of analytical grade.</p></sec><sec id="section4-2050312120973499"><title>Plant extracts</title><p>REVERC3<sup>TM</sup>, a standardized turmeric extract enriched with BDMC, and
regular turmeric extract were procured from the Department of Phytochemistry,
R&#x00026;D Center for Excellence, Vidya Herbs Pvt. Ltd., Bangalore, India.</p></sec><sec id="section5-2050312120973499"><title>High-performance liquid chromatography analysis</title><p>Quantification of BDMC in REVERC3 was performed by high-performance liquid
chromatography (HPLC) on a Shimadzu LC2030C Prominence-i (Japan) system at UV
detection of 420&#x02009;nm. Separation was carried out in Kinetex C-18 column (100&#x02009;&#x001fa;,
150&#x02009;mm&#x02009;&#x000d7;&#x02009;4.6&#x02009;mm, 5&#x02009;&#x003bc;m pore size) with a mobile phase of water: tetrahydrofuran
(60:40) flowed at 1&#x02009;mL/min. BDMC peak was identified based on retention time
(RT) matched with the corresponding reference standard.</p></sec><sec id="section6-2050312120973499"><title>Enzyme inhibition by Ellman assay</title><p>The inhibition of cholinesterase activities was determined using Ellman&#x02019;s assay<sup><xref rid="bibr26-2050312120973499" ref-type="bibr">26</xref></sup> with modifications in the concentration of the substrate and enzyme used.
Briefly, 200&#x02009;&#x000b5;L of the reaction mixture in a 96-well plate contained 5&#x02009;&#x000b5;L of
AChE (0.012&#x02009;U/mL, pH 7.8 sodium phosphate buffer) or BuChE (0.05&#x02009;U/mL, pH 7.8
sodium phosphate buffer), 100&#x02009;&#x000b5;L of DTNB (1.5&#x02009;mM in pH 7.8 sodium phosphate
buffer), and 20&#x02009;&#x000b5;L of different concentrations of REVERC3 or galantamine. The
reaction mixture was incubated at 25&#x000b0;C for 10&#x02009;min and then 5&#x02009;&#x000b5;L of the
respective substrate solutions for AChE (0.75&#x02009;mM ATC) or BuChE (0.75&#x02009;mM BTC)
assays were added to initiate the reaction. After 15&#x02009;min incubation, the
absorbance was measured at 405&#x02009;nm using Ascent Multiskan EX plate reader. The
assays were performed in triplicates. The percentage of inhibition was
calculated as follows</p><p>
<disp-formula id="disp-formula1-2050312120973499"><alternatives><mml:math id="math1-2050312120973499"><mml:mrow><mml:mo>%</mml:mo><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">Inhibition</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mo>&#x02212;</mml:mo><mml:mspace width="0.25em"/><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">B</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi mathvariant="normal">a</mml:mi></mml:mrow></mml:mfrac><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math><graphic xlink:href="10.1177_2050312120973499-eq1.jpg" position="float" orientation="portrait"/></alternatives></disp-formula>
</p><p>where, A is the enzyme activity without inhibitor; B is the activity with
inhibitor; a and b are the negative controls without and with inhibitor,
respectively.</p><p>IC50 was determined by nonlinear regression analysis performed using GraphPad
Prism, version 5.0 (GraphPad Software, San Diego, CA, USA).</p></sec><sec id="section7-2050312120973499"><title>Kinetic analysis of enzyme inhibition</title><p>The kinetics of inhibition of AChE and BuChE activities at various substrate and
inhibitor concentrations were studied. Two concentrations of REVERC3 and
galantamine were evaluated for inhibition of enzyme activity using different ATC
(0.1, 0.2, and 0.4) and BTC (0.1, 0.25, 0.5, 0.75, and 1&#x02009;mM) substrate
concentrations. The changes in reaction velocity were determined as a function
of maximum velocity (V<sub>max</sub>) and Michaelis constant (K<sub>m</sub>).
The pattern of inhibition was determined using Lineweaver&#x02013;Burk (L-B) double
reciprocal plot, where a graph of 1/change in absorbance (&#x00394;Ab/min) was plotted
against 1/[substrate]. The identification of the type of inhibition was based on
point of intersection of lines. The L-B plots and kinetic parameters
K<sub>m</sub> and V<sub>max</sub> were obtained using GraphPad Prism.</p></sec><sec id="section8-2050312120973499"><title>Molecular docking</title><p>The crystal structures of recombinant human AChE bound to donepezil (PDB ID:
4EY7, R&#x02009;=&#x02009;2.35&#x02009;&#x001fa;) and BuChE (PDB ID: 1P0P, R&#x02009;=&#x02009;2.30&#x02009;&#x001fa;) bound to BTC were
downloaded from PDB database (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/">http://www.rcsb.org/</ext-link>) in .pdb
format. The coordinates of PDB structures were prepared for molecular docking by
removing the water ions and ligands using Python molecule viewer. AutoDock tool
(ADT 1.5.4) was used to add polar hydrogens and Gasteiger charges. The
three-dimensional (3D) structure of BDMC was obtained from Pubchem (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov">https://pubchem.ncbi.nlm.nih.gov</ext-link>). The druggability was
determined using SWISSADME prediction (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>).
3D coordinates were prepared using PRODRG server.</p><p>The active site amino acid residues of AChE and BuChE were retrieved from the
literature.<sup><xref rid="bibr27-2050312120973499" ref-type="bibr">27</xref>,<xref rid="bibr28-2050312120973499" ref-type="bibr">28</xref></sup> Molecular docking was performed using AutoDock 4.2.
Autogrid was utilized to prepare the grid maps using a grid box size of
50&#x02009;&#x000d7;&#x02009;50&#x02009;&#x000d7;&#x02009;50 xyz points and the active site of AChE (x&#x02009;=&#x02009;20.823, y&#x02009;=&#x02009;16.078, and
z&#x02009;=&#x02009;18.939) and BuChE (x&#x02009;=&#x02009;137.156, y&#x02009;=&#x02009;113.437, z&#x02009;=&#x02009;43.769). The Lamarckian
genetic algorithm and the pseudo-Solis and Wets methods were applied for
minimization, using default parameters.</p></sec><sec id="section9-2050312120973499"><title>Statistical analysis</title><p>IC50 was determined using nonlinear regression analysis and Lineweaver&#x02013;Burk plots
were drawn using linear regression analysis. The analyses were performed, and
the graphics generated by GraphPad Prism 5.0.</p></sec></sec><sec sec-type="results" id="section10-2050312120973499"><title>Results</title><sec id="section11-2050312120973499"><title>Quantitative analysis of curcuminoids in REVERC3</title><p>The curcuminoids were quantified in REVERC3 by HPLC analysis (<xref ref-type="fig" rid="fig1-2050312120973499">Figure 1</xref>). The extract has
&#x0003e;70% BDMC, &#x0003e;2% curcumin, and &#x0003e;6% DMC.</p><fig id="fig1-2050312120973499" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>HPLC chromatogram of bisdemethoxycurcumin reference standard (a) and
REVERC3 (b).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig1"/></fig></sec><sec id="section12-2050312120973499"><title>Determination of cholinesterase inhibition activity</title><p>The cholinesterase inhibitory potentials of REVERC3 was determined and compared
with regular turmeric extract. Galantamine was used as the standard inhibitor.
<xref rid="table1-2050312120973499" ref-type="table">Table 1</xref> and
<xref ref-type="fig" rid="fig2-2050312120973499">Figure 2</xref> shows the
results of the inhibition assay performed against AChE and BuChE enzymes. As
expected, galantamine was far the most potent inhibitor of cholinesterases with
IC50 values of 0.31 and 9.9&#x02009;&#x000b5;g/mL for AChE and BuChE activities, respectively.
REVERC3 exhibited higher AChE inhibitory activity (IC50 29.08&#x02009;&#x000b5;g/mL) compared to
regular turmeric extract (IC50 139.2&#x02009;&#x000b5;g/mL). REVERC3 and turmeric extract showed
93.8- and 449.03-fold difference relative to galantamine, respectively. A
similar trend was observed in BuChE inhibition. REVERC3 demonstrated greater
potency with an IC50 value of 33.59&#x02009;&#x000b5;g/mL compared to regular turmeric extract
(180.9&#x02009;&#x000b5;g/mL).</p><table-wrap id="table1-2050312120973499" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Comparison of IC50 values of inhibitors against acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE).</p></caption><alternatives><graphic xlink:href="10.1177_2050312120973499-table1"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Inhibitor</th><th align="left" rowspan="1" colspan="1">AChE IC50 value (&#x000b5;g/mL)</th><th align="left" rowspan="1" colspan="1">Fold difference relative to galantamine</th><th align="left" rowspan="1" colspan="1">BuChE IC50 value</th><th align="left" rowspan="1" colspan="1">Fold difference relative to galantamine</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Galantamine</td><td rowspan="1" colspan="1">0.31</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">9.9</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">REVERC3</td><td rowspan="1" colspan="1">29.08</td><td rowspan="1" colspan="1">93.8</td><td rowspan="1" colspan="1">33.59</td><td rowspan="1" colspan="1">3.39</td></tr><tr><td rowspan="1" colspan="1">Regular turmeric extract</td><td rowspan="1" colspan="1">139.2</td><td rowspan="1" colspan="1">449.03</td><td rowspan="1" colspan="1">180.9</td><td rowspan="1" colspan="1">18.27</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-2050312120973499"><p>AChE: acetylcholinesterase; BChE: butyrylcholinesterase.</p></fn></table-wrap-foot></table-wrap><fig id="fig2-2050312120973499" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Determination of inhibitory effect of REVERC3 against the
cholinesterases. The activities of acetylcholinesterase (AChE) (a) and
butyrylcholinesterase (BuChE) (b) were measured in the presence of
different concentrations of inhibitors.</p></caption><graphic xlink:href="10.1177_2050312120973499-fig2"/></fig></sec><sec id="section13-2050312120973499"><title>Inhibition kinetics of cholinesterases</title><p>AChE kinetic analysis was performed using different substrate and inhibitor
concentrations. <xref ref-type="fig" rid="fig3-2050312120973499">Figure
3a</xref> shows the Michaelis&#x02013;Menten graph and the reciprocal L-B plot of
AChE activity in the presence and absence of galantamine. From the data, it
appears that galantamine exhibits mixed inhibition of AChE. On the contrary, it
was observed from the kinetic analysis that REVERC3 demonstrated a competitive
mode of inhibition (<xref ref-type="fig" rid="fig3-2050312120973499">Figure
3b</xref>).</p><fig id="fig3-2050312120973499" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Inhibition kinetics of acetylcholinesterase (AChE) activity in the
presence of different concentrations of substrate and the inhibitor. The
data are presented as graphics of nonlinear (Michaelis&#x02013;Menten graph) and
linear regressions (Lineweaver&#x02013;Burk plots) in the presence or absence of
two concentrations of galantamine (a) and REVERC3 (b).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig3"/></fig><p>Different concentrations of galantamine and REVERC3 were further tested for the
inhibition of BuChE enzyme and the kinetic parameters determined. Galantamine
was found to inhibit the enzyme activity competitively (<xref ref-type="fig" rid="fig4-2050312120973499">Figure 4a</xref>), whereas REVERC3 exhibited
uncompetitive inhibition (<xref ref-type="fig" rid="fig4-2050312120973499">Figure 4b</xref>). REVERC3 had reduced V<sub>max</sub> (0.04) and
K<sub>m</sub> (139&#x02009;&#x000b5;M) values compared to the enzyme activity without
inhibitor (V<sub>max</sub> 0.08, K<sub>m</sub> 289.4&#x02009;&#x000b5;M).</p><fig id="fig4-2050312120973499" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Kinetic analysis of BuChE inhibition. Different concentrations of
galantamine (a) and REVERC3 (b) were incubated with various
concentrations (100&#x02013;1000&#x02009;&#x000b5;M) of butyrylthiocholine iodide (BTC). The
data are presented as graphics of nonlinear (Michaelis&#x02013;Menten graph) and
linear regressions (Lineweaver&#x02013;Burk plots).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig4"/></fig></sec><sec id="section14-2050312120973499"><title>Molecular docking</title><p>BDMC is the major active constituent in REVERC3. Here, we have investigated the
binding position of BDMC into the active sites of cholinesterases. Initially,
SWISSADME was used to predict the druggability of the molecule based on
Lipinski&#x02019;s rule of five. We found that BDMC satisfied the druggability criteria
(<xref rid="table2-2050312120973499" ref-type="table">Table 2</xref>).</p><table-wrap id="table2-2050312120973499" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Drug-like properties of BDMC and galantamine.</p></caption><alternatives><graphic xlink:href="10.1177_2050312120973499-table2"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Lipinski&#x02019;s rule of five</th><th align="left" rowspan="1" colspan="1">BDMC</th><th align="left" rowspan="1" colspan="1">Galantamine</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Molecular weight (&#x0003c;500&#x02009;Da)</td><td rowspan="1" colspan="1">308.33</td><td rowspan="1" colspan="1">287.35</td></tr><tr><td rowspan="1" colspan="1">MLog P (&#x0003c;4.15)</td><td rowspan="1" colspan="1">2.13</td><td rowspan="1" colspan="1">1.74</td></tr><tr><td rowspan="1" colspan="1">H-Bond donor (5)</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">H-Bond acceptor (&#x0003c;10)</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Violation</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn2-2050312120973499"><p>BDMC: bisdemethoxycurcumin.</p></fn></table-wrap-foot></table-wrap><p>AutoDock 4.2 was used to perform the molecular docking analysis. <xref ref-type="fig" rid="fig5-2050312120973499">Figure 5</xref> shows the 3D
crystal structures of the cholinesterases.</p><fig id="fig5-2050312120973499" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>3D crystal structures of acetylcholinesterase (AChE, PDB ID: 4EY7) (a)
and butyrylcholinesterase (BuChE, PDB ID: 1P0P) (b). The protein
structures were retrieved from RCSB Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org">www.rcsb.org</ext-link>/).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig5"/></fig><p>AChE and BuChE enzymes have several domains involved in the substrate binding.<sup><xref rid="bibr26-2050312120973499" ref-type="bibr">26</xref></sup> In the case of AChE, the catalytic triad is formed by Ser203, Glu334, and
His447. The anionic site involved in the binding of choline moiety of ACh
contains the aromatic amino acids: Tyr130, Trp86, Tyr337, and Phe338. Another
important region in the binding site is the acyl pocket required for the
selective binding of ACh (Phe295 and Phe297). Furthermore, the oxyanionic hole
formed by Gly121, Gly122, and Ala204 is the site where the structural water
molecule stabilizes the enzyme-substrate complex. There exist peripheral anionic
site (PAS) in proximity with the catalytic site of the enzyme which
allosterically regulates the catalysis. PAS is formed by five residues: Asp74,
Tyr72, Tyr124, Trp286, and Tyr341 (<xref ref-type="fig" rid="fig6-2050312120973499">Figure 6a</xref>). The human BuChE active site
contains binding domains like AChE. However, the small structural differences in
the active site are evident due to the difference in several amino acid residues
determining the binding domains in the active site (<xref ref-type="fig" rid="fig6-2050312120973499">Figure 6b</xref>).</p><fig id="fig6-2050312120973499" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>Active sites of recombinant human acetylcholinesterase (PDB ID: 4EY7) (a)
and human butyrylcholinesterase (PDB ID: 1P0P) (b).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig6"/></fig><p>BDMC was docked into the active sites of the cholinesterases and the top 10
binding poses were analyzed. The best binding conformation of BDMC with AChE
active site showed profound interaction of the molecule with the
substrate-binding site of the enzyme. BDMC exhibited hydrogen bond interaction
with the key residue Phe295 in the acyl pocket of the active site (<xref ref-type="fig" rid="fig7-2050312120973499">Figure 7a</xref>). The lowest
binding energy was &#x02013;7.3&#x02009;kcal/mol with K<sub>i</sub> value of 4.47&#x02009;&#x003bc;M (<xref rid="table3-2050312120973499" ref-type="table">Table 3</xref>).</p><fig id="fig7-2050312120973499" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Interaction of BDMC with the active site of cholinesterases.
Representative images of BDMC (molecular structure) binding pose
conformation with the active site of AChE (a) and BuChE (b). BDMC was
docked in the active site of BuChE in the presence of the bound
substrate, butyrylthiocholine (Green).</p></caption><graphic xlink:href="10.1177_2050312120973499-fig7"/></fig><table-wrap id="table3-2050312120973499" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Molecular docking analysis of BDMC against cholinesterase active
sites.</p></caption><alternatives><graphic xlink:href="10.1177_2050312120973499-table3"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Enzyme</th><th align="left" rowspan="1" colspan="1">Binding energy (kcal/mol)</th><th align="left" rowspan="1" colspan="1">Ligand efficiency</th><th align="left" rowspan="1" colspan="1">Inhibition constant (&#x003bc;M)</th><th align="left" rowspan="1" colspan="1">Intermolecular energy</th><th align="left" rowspan="1" colspan="1">VDW-H bond desolvation energy</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AChE</td><td rowspan="1" colspan="1">&#x02212;7.3</td><td rowspan="1" colspan="1">&#x02212;0.32</td><td rowspan="1" colspan="1">4.47</td><td rowspan="1" colspan="1">&#x02212;10.28</td><td rowspan="1" colspan="1">&#x02212;10.16</td></tr><tr><td rowspan="1" colspan="1">BuChE</td><td rowspan="1" colspan="1">&#x02212;7.27</td><td rowspan="1" colspan="1">&#x02212;0.32</td><td rowspan="1" colspan="1">4.73</td><td rowspan="1" colspan="1">&#x02212;10.25</td><td rowspan="1" colspan="1">&#x02212;10.09</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-2050312120973499"><p>AChE: acetylcholinesterase; BChE: butyrylcholinesterase; BDMC:
bisdemethoxycurcumin; VDW-H: Van der Walls-H-bond.</p></fn></table-wrap-foot></table-wrap><p>The preference of BDMC for the binding site of BuChE was different as compared to
that for AChE. Here, we have used the substrate (BTC) bound enzyme as the
receptor. BDMC was found to have H-bond interactions with the key residues of
the catalytic triad His438 and Ser198. The affinity of BDMC with the
enzyme-substrate complex was appreciable (Ki&#x02009;=&#x02009;4.73&#x02009;&#x003bc;M) with a binding energy of
&#x02013;7.27&#x02009;kcal/mol.</p></sec></sec><sec sec-type="discussion" id="section15-2050312120973499"><title>Discussion</title><p>Age-related deterioration of health conditions includes loss of cognitive functions
due to the decline in cholinergic transmission as a result of disturbances in the
ACh metabolism in the brain.<sup><xref rid="bibr29-2050312120973499" ref-type="bibr">29</xref></sup> In this regard, cholinesterases are the prime targets in the treatment of AD.<sup><xref rid="bibr30-2050312120973499" ref-type="bibr">30</xref></sup> AChE inhibitors including natural plant alkaloid galantamine have been
clinically tested to improve the cholinergic functions.<sup><xref rid="bibr31-2050312120973499" ref-type="bibr">31</xref></sup> In this study, we have evaluated the cholinesterase inhibitory effect of a
standardized turmeric extract containing more than 70% BDMC. Conventionally regular
turmeric extract contains curcumin as the major curcuminoid and the content of BDMC
is only 2%&#x02013;3%. Here, we have used a BDMC-enriched extract (REVERC3) to study the
possible mechanism of cholinesterase inhibition. Initially, the cholinesterase
enzyme inhibition assays were performed using different concentrations of REVERC3
and the regular turmeric extract. Interestingly, REVERC3 demonstrated higher
inhibitory activity compared to the regular turmeric extract. Furthermore, the
BDMC-enriched extract was found to inhibit both AChE and BuChE activities
appreciably. The respective IC50 values of REVERC3 for the inhibition of AChE and
BuChE were 4.8- and 5.39-fold lower relative to regular curcumin. The drastic
increase in the inhibitory ability of REVERC3 could be largely attributed to the
enriched content of BDMC in the extract.</p><p>Furthermore, we have determined the mode of inhibition of the cholinesterases by
galantamine and REVERC3 using LB reciprocal plots. The extract exhibited competitive
inhibition of AChE activity. The K<sub>m</sub> value was increased while
V<sub>max</sub> remained unaffected in the presence of REVERC3. Previously,
galantamine was found to competitively inhibit AChE activity.<sup><xref rid="bibr32-2050312120973499" ref-type="bibr">32</xref></sup> However, in this study, galantamine demonstrated mixed inhibition. This could
be explained by the difference in the experimental conditions. REVERC3 showed the
uncompetitive mode of inhibition of BuChE activity as the V<sub>max</sub> and
K<sub>m</sub> were reduced in the presence of the extract. Galantamine appeared
to exhibit competitive inhibition.</p><p>Based on the inhibition data, we further rationalized the role of BDMC in REVERC3 by
predicting its binding into the active sites of cholinesterases. Molecular docking
analysis revealed that BDMC could strongly interact with the catalytic site of AChE
with low binding energy and K<sub>i</sub> value. It was observed that the molecule
had H-bond interaction with Phe295 residue in the acyl pocket of the active site.
The competitive nature of inhibition of REVERC3 is well supported by the docked
binding poses.</p><p>Further to investigate the interactions of BDMC with the active site residues of
BuChE, we have used the substrate-bound protein as the receptor. The substrate was
found to have interactions with the active gorge residues especially the Asp70 in
the PAS region. BDMC could strongly interact with Ser198 and His438 residues in the
catalytic domain, in presence of the substrate. This could explain the mode of
binding of BDMC exerting the uncompetitive inhibition of BuChE.</p><p>There are several studies reporting the beneficial role of curcumin in cognitive
improvement and Alzheimer&#x02019;s pathological manifestations such as A&#x003b2;
aggregation.<sup><xref rid="bibr33-2050312120973499" ref-type="bibr">33</xref>,<xref rid="bibr34-2050312120973499" ref-type="bibr">34</xref></sup> However, the poor bioavailability of curcumin cannot be ignored.<sup><xref rid="bibr35-2050312120973499" ref-type="bibr">35</xref></sup> This study unveils the improved benefits of BDMC over curcumin in inhibiting
the key enzymes associated with neurodegeneration. Previously, it has been shown
that BDMC is comparatively more stable than curcumin in physiological conditions.<sup><xref rid="bibr36-2050312120973499" ref-type="bibr">36</xref></sup> Findings from our study rationalize the use of a BDMC-rich turmeric extract
as a functional ingredient in food and health supplements for brain health. The
present investigation however is limited to the in vitro studies. Further insights
into the molecular aspects related to neuronal health such as A&#x003b2; aggregation and
toxicity, tau hyperphosphorylation and neurotransmission using cellular and
preclinical models are required to validate the neuroprotective properties of
BDMC.</p></sec><sec sec-type="conclusions" id="section16-2050312120973499"><title>Conclusion</title><p>Data from this study provides preliminary evidence on the possible role of a
BDMC-rich turmeric extract in mitigating the cognitive deficits as a function of
cholinesterase inhibition. Furthermore, it is important to note that REVERC3 could
act as a dual inhibitor of cholinesterases which substantiates the potential
neuroprotective effects of BDMC.</p></sec></body><back><fn-group><fn fn-type="con"><p><bold>Authors&#x02019; contributions:</bold> S.K. contributed to conceptualization. S.H.V., G.K., and A.R. contributed to
inhibition and kinetic studies. S.H.V. contributed to computational analysis.
C.S. contributed to analytical data analysis. S.K. contributed to supervision.
S.H.V. and A.R. contributed to writing&#x02014;original draft. S.H.V. and S.K.
contributed to writing&#x02014;review and editing.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of conflicting interests:</bold> The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) received no financial support for the research, authorship, and/or
publication of this article.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Sudeep HV <inline-graphic xlink:href="10.1177_2050312120973499-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-1287-9617">https://orcid.org/0000-0003-1287-9617</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2050312120973499"><label>1</label><mixed-citation publication-type="web">
<collab>NICE</collab>. <article-title>Dementia</article-title>,
<year>2019</year>, <ext-link ext-link-type="uri" xlink:href="https://cks.nice.org.uk/dementia">https://cks.nice.org.uk/dementia</ext-link> (<comment>accessed 20 January
2020</comment>).</mixed-citation></ref><ref id="bibr2-2050312120973499"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gale</surname><given-names>SA</given-names></name><name><surname>Acar</surname><given-names>D</given-names></name><name><surname>Daffner</surname><given-names>KR.</given-names></name></person-group>
<article-title>Dementia</article-title>. <source>Am J Med</source>
<year>2018</year>; <volume>131</volume>:
<fpage>1161</fpage>&#x02013;<lpage>1169</lpage>.<pub-id pub-id-type="pmid">29425707</pub-id></mixed-citation></ref><ref id="bibr3-2050312120973499"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Mesulam</surname><given-names>MM</given-names></name><name><surname>Cuello</surname><given-names>AC</given-names></name></person-group>, <etal>et al</etal>
<article-title>The cholinergic system in
the pathophysiology and treatment of Alzheimer&#x02019;s disease</article-title>.
<source>Brain</source>
<year>2018</year>; <volume>141</volume>:
<fpage>1917</fpage>&#x02013;<lpage>1933</lpage>.<pub-id pub-id-type="pmid">29850777</pub-id></mixed-citation></ref><ref id="bibr4-2050312120973499"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Querfurth</surname><given-names>HW</given-names></name><name><surname>LaFerla</surname><given-names>FM.</given-names></name></person-group>
<article-title>Alzheimer&#x02019;s disease</article-title>. <source>N Engl J
Med</source>
<year>2010</year>; <volume>362</volume>:
<fpage>329</fpage>&#x02013;<lpage>344</lpage>.<pub-id pub-id-type="pmid">20107219</pub-id></mixed-citation></ref><ref id="bibr5-2050312120973499"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barbier</surname><given-names>P</given-names></name><name><surname>Zejneli</surname><given-names>O</given-names></name><name><surname>Martinho</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Role of tau as a
microtubule-associated protein: structural and functional
aspects</article-title>. <source>Front Aging Neurosci</source>
<year>2019</year>; <volume>11</volume>: <fpage>204</fpage>.<pub-id pub-id-type="pmid">31447664</pub-id></mixed-citation></ref><ref id="bibr6-2050312120973499"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chintamaneni</surname><given-names>M</given-names></name><name><surname>Bhaskar</surname><given-names>M.</given-names></name></person-group>
<article-title>Biomarkers in Alzheimer&#x02019;s disease: a review</article-title>.
<source>ISRN Pharmacol</source>
<year>2012</year>; <volume>2012</volume>:
<fpage>984786</fpage>.<pub-id pub-id-type="pmid">22811931</pub-id></mixed-citation></ref><ref id="bibr7-2050312120973499"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cipriani</surname><given-names>G</given-names></name><name><surname>Danti</surname><given-names>S</given-names></name><name><surname>Vedovello</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Understanding delusion in
dementia: a review</article-title>. <source>Geriatr Gerontol Int</source>
<year>2014</year>; <volume>14</volume>:
<fpage>32</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">23879399</pub-id></mixed-citation></ref><ref id="bibr8-2050312120973499"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira-Vieira</surname><given-names>TH</given-names></name><name><surname>Guimaraes</surname><given-names>IM</given-names></name><name><surname>Silva</surname><given-names>FR</given-names></name></person-group>, <etal>et al</etal>
<article-title>Alzheimer&#x02019;s disease:
targeting the cholinergic system</article-title>. <source>Curr
Neuropharmacol</source>
<year>2016</year>; <volume>14</volume>:
<fpage>101</fpage>&#x02013;<lpage>115</lpage>.<pub-id pub-id-type="pmid">26813123</pub-id></mixed-citation></ref><ref id="bibr9-2050312120973499"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McMahan</surname><given-names>UJ</given-names></name><name><surname>Sanes</surname><given-names>JR</given-names></name><name><surname>Marshall</surname><given-names>LM.</given-names></name></person-group>
<article-title>Cholinesterase is associated with the basal lamina at the
neuromuscular junction</article-title>. <source>Nature</source>
<year>1978</year>; <volume>271</volume>:
<fpage>172</fpage>&#x02013;<lpage>174</lpage>.<pub-id pub-id-type="pmid">622157</pub-id></mixed-citation></ref><ref id="bibr10-2050312120973499"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>, <etal>et al</etal>
<article-title>Recent progress in the
identification of selective butyrylcholinesterase inhibitors for Alzheimer&#x02019;s
disease</article-title>. <source>Eur J Med Chem</source>
<year>2017</year>; <volume>132</volume>:
<fpage>294</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">28371641</pub-id></mixed-citation></ref><ref id="bibr11-2050312120973499"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Telpoukhovskaia</surname><given-names>MA</given-names></name><name><surname>Patrick</surname><given-names>BO</given-names></name><name><surname>Rodr&#x000ed;guez-Rodr&#x000ed;guez</surname><given-names>C</given-names></name></person-group>, <etal>et al</etal>
<article-title>In silico to in vitro
screening of hydroxypyridinones as acetylcholinesterase
inhibitors</article-title>. <source>Bioorg Med Chem Lett</source>
<year>2016</year>; <volume>26</volume>:
<fpage>1624</fpage>&#x02013;<lpage>1628</lpage>.<pub-id pub-id-type="pmid">26869193</pub-id></mixed-citation></ref><ref id="bibr12-2050312120973499"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>&#x0010c;olovi&#x00107;</surname><given-names>MB</given-names></name><name><surname>Krsti&#x00107;</surname><given-names>DZ</given-names></name><name><surname>Lazarevi&#x00107;-Pa&#x00161;ti</surname><given-names>TD</given-names></name></person-group>, <etal>et al</etal>
<article-title>Acetylcholinesterase
inhibitors: pharmacology and toxicology</article-title>. <source>Curr
Neuropharmacol</source>
<year>2013</year>; <volume>11</volume>(<issue>3</issue>):
<fpage>315</fpage>&#x02013;<lpage>335</lpage>.<pub-id pub-id-type="pmid">24179466</pub-id></mixed-citation></ref><ref id="bibr13-2050312120973499"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lilienfeld</surname><given-names>S.</given-names></name></person-group>
<article-title>Galantamine: a novel cholinergic drug with a unique dual mode of
action for the treatment of patients with Alzheimer&#x02019;s
disease</article-title>. <source>CNS Drug Rev</source>
<year>2002</year>; <volume>8</volume>(<issue>2</issue>):
<fpage>159</fpage>&#x02013;<lpage>176</lpage>.<pub-id pub-id-type="pmid">12177686</pub-id></mixed-citation></ref><ref id="bibr14-2050312120973499"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khoury</surname><given-names>R</given-names></name><name><surname>Rajamanickam</surname><given-names>J</given-names></name><name><surname>Grossberg</surname><given-names>GT.</given-names></name></person-group>
<article-title>An update on the safety of current therapies for Alzheimer&#x02019;s
disease: focus on rivastigmine</article-title>. <source>Ther Adv Drug
Saf</source>
<year>2018</year>; <volume>9</volume>(<issue>3</issue>):
<fpage>171</fpage>&#x02013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">29492246</pub-id></mixed-citation></ref><ref id="bibr15-2050312120973499"><label>15</label><mixed-citation publication-type="web">
<collab>NICE</collab>. <article-title>Galantamine</article-title>,
<year>2018</year>, <ext-link ext-link-type="uri" xlink:href="https://bnf.nice.org.uk/drug/galantamine.html">https://bnf.nice.org.uk/drug/galantamine.html</ext-link> (<comment>accessed
20 January 2020</comment>).</mixed-citation></ref><ref id="bibr16-2050312120973499"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ayaz</surname><given-names>M</given-names></name><name><surname>Sadiq</surname><given-names>A</given-names></name><name><surname>Junaid</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Neuroprotective and
anti-aging potentials of essential oils from aromatic and medicinal
plants</article-title>. <source>Front Aging Neurosci</source>
<year>2017</year>; <volume>9</volume>: <fpage>168</fpage>.<pub-id pub-id-type="pmid">28611658</pub-id></mixed-citation></ref><ref id="bibr17-2050312120973499"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sahoo</surname><given-names>AK</given-names></name><name><surname>Dandapat</surname><given-names>J</given-names></name><name><surname>Dash</surname><given-names>UC</given-names></name></person-group>, <etal>et al</etal>
<article-title>Features and outcomes of
drugs for combination therapy as multi-targets strategy to combat
Alzheimer&#x02019;s disease</article-title>. <source>J Ethnopharmacol</source>
<year>2018</year>; <volume>215</volume>:
<fpage>42</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29248451</pub-id></mixed-citation></ref><ref id="bibr18-2050312120973499"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ammon</surname><given-names>HPT</given-names></name><name><surname>Wahl</surname><given-names>MA</given-names></name></person-group>
<article-title>Pharmacology of</article-title>
<source>Curcuma longa. Planta Med</source>
<year>1991</year>; <volume>57</volume>(<issue>1</issue>):
<fpage>1</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">2062949</pub-id></mixed-citation></ref><ref id="bibr19-2050312120973499"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hewlings</surname><given-names>SJ</given-names></name><name><surname>Kalman</surname><given-names>DS.</given-names></name></person-group>
<article-title>Curcumin: a review of its&#x02019; effects on human
health</article-title>. <source>Foods</source>
<year>2017</year>; <volume>6</volume>(<issue>10</issue>):
<fpage>92</fpage>.</mixed-citation></ref><ref id="bibr20-2050312120973499"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>R</given-names></name></person-group>, <etal>et al</etal>
<article-title>Combinatorial anticancer
effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt
and ERK pathways</article-title>. <source>Nat Prod Res</source>
<year>2016</year>; <volume>30</volume>:
<fpage>1858</fpage>&#x02013;<lpage>1861</lpage>.<pub-id pub-id-type="pmid">26299635</pub-id></mixed-citation></ref><ref id="bibr21-2050312120973499"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Maione</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>R</given-names></name><name><surname>Khan</surname><given-names>H</given-names></name></person-group>, <etal>et al</etal>
<article-title>Medicinal plants with
anti-inflammatory activities</article-title>. <source>Nat Prod Res</source>
<year>2016</year>; <volume>30</volume>:
<fpage>1343</fpage>&#x02013;<lpage>1352</lpage>.<pub-id pub-id-type="pmid">26221780</pub-id></mixed-citation></ref><ref id="bibr22-2050312120973499"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandur</surname><given-names>SK</given-names></name><name><surname>Pandey</surname><given-names>MK</given-names></name><name><surname>Sung</surname><given-names>B</given-names></name></person-group>, <etal>et al</etal>
<article-title>Curcumin, demethoxycurcumin,
bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially
regulate anti-inflammatory and anti-proliferative responses through a
ROS-independent mechanism</article-title>. <source>Carcinogenesis</source>
<year>2007</year>; <volume>28</volume>(<issue>8</issue>):
<fpage>1765</fpage>&#x02013;<lpage>1773</lpage>.<pub-id pub-id-type="pmid">17522064</pub-id></mixed-citation></ref><ref id="bibr23-2050312120973499"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>CC</given-names></name><name><surname>Yang</surname><given-names>MD</given-names></name><name><surname>Lin</surname><given-names>HY</given-names></name></person-group>, <etal>et al</etal>
<article-title>Bisdemethoxycurcumin (BDMC)
alters gene expression-associated cell cycle, cell migration and invasion
and tumor progression in human lung cancer NCI-H460 cells</article-title>.
<source>In Vivo</source>
<year>2015</year>; <volume>29</volume>(<issue>6</issue>):
<fpage>711</fpage>&#x02013;<lpage>728</lpage>.<pub-id pub-id-type="pmid">26546528</pub-id></mixed-citation></ref><ref id="bibr24-2050312120973499"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yodkeeree</surname><given-names>S</given-names></name><name><surname>Chaiwangyen</surname><given-names>W</given-names></name><name><surname>Garbisa</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Curcumin, demethoxycurcumin
and bisdemethoxycurcumin differentially inhibit cancer cell invasion through
the down-regulation of MMPs and uPA</article-title>. <source>J Nutr
Biochem</source>
<year>2009</year>; <volume>20</volume>(<issue>2</issue>):
<fpage>87</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">18495463</pub-id></mixed-citation></ref><ref id="bibr25-2050312120973499"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalayc&#x00131;o&#x0011f;lu</surname><given-names>Z</given-names></name><name><surname>Gazio&#x0011f;lu</surname><given-names>I</given-names></name><name><surname>Erim</surname><given-names>FB.</given-names></name></person-group>
<article-title>Comparison of antioxidant, anticholinesterase, and antidiabetic
activities of three curcuminoids isolated from <italic>Curcuma
longa</italic> L</article-title>. <source>Nat Prod Res</source>
<year>2017</year>; <volume>31</volume>(<issue>24</issue>):
<fpage>2914</fpage>&#x02013;<lpage>2917</lpage>.<pub-id pub-id-type="pmid">28287280</pub-id></mixed-citation></ref><ref id="bibr26-2050312120973499"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ellman</surname><given-names>GL</given-names></name><name><surname>Courtney</surname><given-names>KD</given-names></name><name><surname>Andres</surname><given-names>V</given-names><suffix>Jr</suffix></name></person-group>, <etal>et al</etal>
<article-title>A new and rapid colorimetric
determination of acetylcholinesterase activity</article-title>.
<source>Biochem Pharmacol</source>
<year>1961</year>; <volume>7</volume>:
<fpage>88</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">13726518</pub-id></mixed-citation></ref><ref id="bibr27-2050312120973499"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Stavrakov</surname><given-names>G</given-names></name><name><surname>Philipova</surname><given-names>I</given-names></name><name><surname>Zheleva</surname><given-names>D</given-names></name></person-group>, <etal>et al</etal>
<article-title>Docking-based design of
galantamine derivatives with dual-site binding to
acetylcholinesterase</article-title>. <source>Mol Inform</source>
<year>2016</year>; <volume>35</volume>(<issue>6&#x02013;7</issue>):
<fpage>278</fpage>&#x02013;<lpage>285</lpage>.<pub-id pub-id-type="pmid">27492242</pub-id></mixed-citation></ref><ref id="bibr28-2050312120973499"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bajda</surname><given-names>M</given-names></name><name><surname>Wi&#x00119;ckowska</surname><given-names>A</given-names></name><name><surname>Hebda</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>Structure-based search for
new inhibitors of cholinesterases</article-title>. <source>Int J Mol
Sci</source>
<year>2013</year>; <volume>14</volume>(<issue>3</issue>):
<fpage>5608</fpage>&#x02013;<lpage>5632</lpage>.<pub-id pub-id-type="pmid">23478436</pub-id></mixed-citation></ref><ref id="bibr29-2050312120973499"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Muir</surname><given-names>JL.</given-names></name></person-group>
<article-title>Acetylcholine, aging, and Alzheimer&#x02019;s disease</article-title>.
<source>Pharmacol Biochem Behav</source>
<year>1997</year>; <volume>56</volume>(<issue>4</issue>):
<fpage>687</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">9130295</pub-id></mixed-citation></ref><ref id="bibr30-2050312120973499"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francis</surname><given-names>PT</given-names></name><name><surname>Palmer</surname><given-names>AM</given-names></name><name><surname>Snape</surname><given-names>M</given-names></name></person-group>, <etal>et al</etal>
<article-title>The cholinergic hypothesis
of Alzheimer&#x02019;s disease: a review of progress</article-title>. <source>J
Neurol Neurosurg Psychiatry</source>
<year>1999</year>; <volume>66</volume>:
<fpage>137</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">10071091</pub-id></mixed-citation></ref><ref id="bibr31-2050312120973499"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murray</surname><given-names>AP</given-names></name><name><surname>Faraoni</surname><given-names>MB</given-names></name><name><surname>Castro</surname><given-names>MJ</given-names></name></person-group>, <etal>et al</etal>
<article-title>Natural AChE inhibitors from
plants and their contribution to Alzheimer&#x02019;s disease
therapy</article-title>. <source>Curr Neuropharmacol</source>
<year>2013</year>; <volume>11</volume>(<issue>4</issue>):
<fpage>388</fpage>&#x02013;<lpage>413</lpage>.<pub-id pub-id-type="pmid">24381530</pub-id></mixed-citation></ref><ref id="bibr32-2050312120973499"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okello</surname><given-names>EJ</given-names></name><name><surname>Mather</surname><given-names>J.</given-names></name></person-group>
<article-title>Comparative kinetics of acetyl- and butyryl-cholinesterase
inhibition by green tea catechins|relevance to the symptomatic treatment of
Alzheimer&#x02019;s disease</article-title>. <source>Nutrients</source>
<year>2020</year>; <volume>12</volume>(<issue>4</issue>):
<year>1090</year>.</mixed-citation></ref><ref id="bibr33-2050312120973499"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PH</given-names></name><name><surname>Manczak</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Protective effects of Indian
spice curcumin against amyloid-&#x003b2; in Alzheimer&#x02019;s disease</article-title>.
<source>J Alzheimers Dis</source>
<year>2018</year>; <volume>61</volume>(<issue>3</issue>):
<fpage>843</fpage>&#x02013;<lpage>866</lpage>.<pub-id pub-id-type="pmid">29332042</pub-id></mixed-citation></ref><ref id="bibr34-2050312120973499"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>PH</given-names></name><name><surname>Manczak</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>X</given-names></name></person-group>, <etal>et al</etal>
<article-title>Protective effects of a
natural product, curcumin, against amyloid &#x003b2; induced mitochondrial and
synaptic toxicities in Alzheimer&#x02019;s disease</article-title>. <source>J
Investig Med</source>
<year>2016</year>; <volume>64</volume>:
<fpage>1220</fpage>&#x02013;<lpage>1234</lpage>.</mixed-citation></ref><ref id="bibr35-2050312120973499"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Taghibiglou</surname><given-names>C.</given-names></name></person-group>
<article-title>The mechanisms of action of curcumin in Alzheimer&#x02019;s
disease</article-title>. <source>J Alzheimers Dis</source>
<year>2017</year>; <volume>58</volume>(<issue>4</issue>):
<fpage>1003</fpage>&#x02013;<lpage>1016</lpage>.<pub-id pub-id-type="pmid">28527218</pub-id></mixed-citation></ref><ref id="bibr36-2050312120973499"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basile</surname><given-names>V</given-names></name><name><surname>Ferrari</surname><given-names>E</given-names></name><name><surname>Lazzari</surname><given-names>S</given-names></name></person-group>, <etal>et al</etal>
<article-title>Curcumin derivatives:
molecular basis of their anti-cancer activity</article-title>.
<source>Biochem Pharmacol</source>
<year>2009</year>; <volume>78</volume>:
<fpage>1305</fpage>&#x02013;<lpage>1315</lpage>.<pub-id pub-id-type="pmid">19580791</pub-id></mixed-citation></ref></ref-list></back></article>